A wave of analyst recommendation removals hit the medical device sector Friday. Seven names — including BSX, EW, DXCM, and ABT — saw recommendations pulled simultaneously. That kind of broad medtech sweep often signals a major firm reorganising its healthcare coverage team.
Boston Scientific was the standout exception. It logged multiple rating changes — not just a removal — with its consensus target slipping to $79.40 from $80.16. The $72B med-device giant has seen its short interest remain low at 2.4% of free float. Bears are not piling in despite the analyst noise.
Stryker saw its average target price trimmed to $389.24 from $389.43. The cut is small. But it matches the cautious tone across the sector.
On the upside, energy and gold attracted fresh analyst support. and both saw consensus target prices nudge higher. also moved up — its target rose to $143.05. At a $117B market cap, Newmont is riding the gold rally. Analyst upgrades here look well-timed.
The split picture — medtech caution versus energy and gold optimism — reflects broader macro positioning heading into June.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
